Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic.
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... ALISO VIEJO, Calif., April 7, 2011 Avanir Pharmaceuticals, ... data from a number of clinical research activities will be ... of Neurology (AAN), taking place in Honolulu, HI, at the ... details about the data presentations:Title: Burden of Pseudobulbar Affect on ...
... Texas, April 7, 2011 Luminex Corporation (Nasdaq: ... Excellence Award in the category of In Vitro Diagnostics ... is a compact, versatile laboratory analysis platform designed to ... from a single sample. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 2Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 3Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting 4Luminex Corporation Wins Prestigious Medical Design Excellence Award 2Luminex Corporation Wins Prestigious Medical Design Excellence Award 3
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... novel compound that targets an important brain receptor has ... behaviors, including relapse behavior, a University at Buffalo animal ... that this may be a novel lead compound for ... The UB research was published as an online preview ... the study, the compound, RO5263397, severely blunted a broad ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... Florida have discovered a key gene that, when turned off, ... findings suggest that a combination of agents now being tested ... on, providing a much-needed therapy for the difficult-to-treat cancer. ... of kidney cancer, accounts for just 3 percent of all ...
... is available in French . Montreal, May 20, ... at the Montreal Heart Institute (MHI) by Dr. Jean-Claude Tardif are ... Tardif is a cardiologist and director of the MHI Research Centre, ... holder of the atherosclerosis research chair at the Universit de Montral. ...
... swarm. Even amoebae clump together in mystifyingly clever constellations. ... the cellular and molecular level to bring about this ... organisms into groups. It,s a choreography seen throughout nature ... as precise as the dance lineup of a Broadway ...
... ... Park Association (NRPA) is reminding Americans to take the proper steps to ensure that their ... The Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) ...
... live inside every person that team plans to sequence ... effort to map out the genetic composition of hundreds ... first results: scientists report they have completed the genome ... , Found in such places as the gastrointestinal tract, ...
... ... 25 New York Verdicts of 2009. Applied Forensics is a 21st Century Forensics Laboratory ... ... Forensics LLP, a laboratory specializing in handwriting analysis, played an integral role in one ...
Cached Medicine News:Health News:Mayo Clinic researchers find gene they believe is key to kidney cancer 2Health News:Mayo Clinic researchers find gene they believe is key to kidney cancer 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Scientists discover the molecular heart of collective behavior 2Health News:Scientists discover the molecular heart of collective behavior 3Health News:Scientists discover the molecular heart of collective behavior 4Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3Health News:Scientists Map Genetic Codes of Human Microbes 2Health News:Scientists Map Genetic Codes of Human Microbes 3Health News:Verdict Search recognizes Applied Forensics in Top 25 New York Verdicts of 2009 2
Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
... A revolutionary urological imaging ... benefits that translate into improved ... x 1k imaging technology physicians ... to see more anatomical detail ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
Medicine Products: